Skip to main content
Clinical Trials/NCT04490629
NCT04490629
Unknown
N/A

A Prospective, Multi-center, Randomized, Parallel-controlled Clinical Trial Evaluating the Efficacy and Safety of Lyoplant Onlay in Repairing Cerebral Dura Mater

Second Affiliated Hospital, School of Medicine, Zhejiang University1 site in 1 country80 target enrollmentNovember 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cerebrospinal Fluid Leak
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment
80
Locations
1
Primary Endpoint
surgical successful rate
Last Updated
5 years ago

Overview

Brief Summary

This prospective, multi-center, randomized, parallel-controlled clinical trial was designed to evaluate the efficacy and safety of Lyoplant Onlay in repairing cerebral dura mater. DURAFORM was regarded as the control group. a total of 80 patients were randomized into experimental and control group (1:1).Data were collected on complications resulting in CSF leaks, surgical site infections, instrument performance parameterized other neurological complications within 30 days. Surgeons also provided data on the ease of use of the dural sealing techniques, as well as preparation and application times. The above-mentioned date were used to evaluate the efficacy and safety of Lyoplant Onlay .

Registry
clinicaltrials.gov
Start Date
November 1, 2019
End Date
November 1, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Any patient between the ages of 18 and 75 years scheduled for elective cranial surgery involving a dural incision.
  • Dural defects and surgical incision was classifed as level 1

Exclusion Criteria

  • local or systemic infection.
  • patients with known allergy to Equipment components
  • a history of traumatic head injury
  • a compromised immune system or autoimmune disease
  • patients who should not participate based on the surgeon's opinion
  • patients participating in any other drug or device trial.
  • expected survival time \<12 months
  • underwent chemoradiotherapy 3 months before randomization
  • uncontrolled diabetes and malignant tumor
  • women who were pregnant, lactating, or wished to become pregnant during the study;

Outcomes

Primary Outcomes

surgical successful rate

Time Frame: at 30 days post surgery

proportion of treated patients free of CSF leak diagnosed by physical examination, biochemical assay, or imaging study within 30 d of the surgical procedure.

Secondary Outcomes

  • neurosurgical complication(2 days post surgery/10 days post surgery/at 30 days post surgery)

Study Sites (1)

Loading locations...

Similar Trials